|
临床相关性
一级信息 关于临床相关性和缩写列表 |
Clinical Relevance
First level information About Clinical Relevance & List of Abbreviations |
►常见于原发性胆汁性胆管炎，但也可在系统性硬化症中检出，包括原发性胆汁性胆管炎-系统性硬化症重叠综合征、原发性胆汁性胆管炎-干燥综合征重叠综合征 (93-97) ►如临床上疑似为原发性胆汁性胆管炎，建议进行AMA的后续检测，该检测历来是用IIFA法在啮齿类动物组织 (肝、胃、肾)上进行；这些自身抗体主要针对PDH复合物，尤其是E2亚基 (PDH-E2)；抗原包含于疾病特异性免疫检测试剂中 (即，肝病谱*)以及一些常规的ENA抗体谱中 (93，94) ►其余所识别的抗原包括PDH的E1α 和 E1β亚基、PDH的E3结合蛋白和2-OGDC；这些抗原仅包含于扩展的疾病特异性免疫检测试剂中 (即，扩展的肝病谱*) (93，94) *肌炎谱、系统性硬化症谱和 (扩展的) 肝病谱可能仅限于专业临床实验室应用。 |
► Commonly found in PBC, but also detected in SSc, including PBC-SSc overlap syndrome and PBC-SjS overlap syndrome (93–97) ► If PBC is clinically suspected it is recommended to perform a follow-up test for AMA, historically detected by IIFA on rodent tissue (liver, stomach, kidney); these autoantibodies are primarily directed to the PDH complex, and in particular the E2-subunit (PDH-E2); the antigen is included in disease specific immunoassays (i.e., liver profile*) as well as in some routine ENA profiles (93, 94) ► Additional antigens recognized include the E1α and E1β subunits of PDH, the E3-binding protein of PDH, and the 2-OGDC; these antigens are only included in extended disease specific immunoassays (i.e., extended liver profile*) (93, 94) *Availability of the inflammatory myopathy profile, the SSc profile and the (extended) liver profile may be limited to specialty clinical laboratories. |
| 一级信息参考文献 | First level information references |
93. European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145–72. 94. Shuai Z, Wang J, Badamagunta M, et al. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology 2017;65:1670–82. 95. Skare TL, Nisihara RM, Haider O, et al. Liver autoantibodies in patients with scleroderma. Clin Rheumatol 2011;30:129–32. 96. Zheng B, Vincent C, Fritzler MJ, et al. Prevalence of systemic sclerosis in primary biliary cholangitis using the new ACR/EULAR classification criteria. J Rheumatol 2017;44:33–9. 97. Nardi N, Brito-Zerón P, Ramos-Casals M, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 2006;25:341–6. |
93. European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145–72. 94. Shuai Z, Wang J, Badamagunta M, et al. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology 2017;65:1670–82. 95. Skare TL, Nisihara RM, Haider O, et al. Liver autoantibodies in patients with scleroderma. Clin Rheumatol 2011;30:129–32. 96. Zheng B, Vincent C, Fritzler MJ, et al. Prevalence of systemic sclerosis in primary biliary cholangitis using the new ACR/EULAR classification criteria. J Rheumatol 2017;44:33–9. 97. Nardi N, Brito-Zerón P, Ramos-Casals M, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 2006;25:341–6. |
| 二级信息 | Second level information |
无 |
None |
| 二级信息参考文献 | Second level information references |
无 |
None |
| FAQ |
| No FAQ received |
Copyright @ ICAP - 2019 Online since 19 May 2015
